TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04252209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: natural herbs of coconut, aloe vera, and pepperint
Description: mixture of herbal oils of coconut, peppermint, aloe vera

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: carboxy methyl cellulose
Description: a moisturizing gel contained 3%carboxy methyl cellulose, 3% peppermint essential oil, 10% propylene glycol, 0.1% potassium sorbate, and water up to 100%.
Study: NCT06087380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: auricular acupressure
Description: Auricular pressure The experimental group commenced auricular acupressure intervention post-surgery. Questionnaire assessments and heart rate variability measurements were conducted in the experimental group on the first, second, third, and fourth days before discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard ward care
Description: standard ward care

Intervention type: OTHER
Group type: OTHER
Intervention: standard ward care
Description: standard ward care
Study: NCT04807738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuroproprioceptive facilitation and inhibition in virtual reality
Description: The 110 outpatients will be randomized into groups: First arm, individual neuroproprioceptive facilitation and inhibition physical therapy combining key principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) in a real environment and the second arm, the same therapy in virtual reality environment. All participants will undergo 15 sessions, 60 minutes each, twice a week in a period of two months.~The therapy in a second, interventional group, uses virtual reality and new software that was developed specifically for inducing and motivating for movement according to principles of proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT). The software allows immediate feedback and moreover, movement is corrected by a present therapist. Evaluation of speed and performance quality might be extracted from the software of virtual reality.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuroproprioceptive facilitation and inhibition
Description: The first arm of the study will consist of a physiotherapeutic approach based on neurophysiological principles using proprioceptive neuromuscular facilitation (PNF) and motor program activating therapy (MPAT) approaches. MPAT makes use of particular motor patterns that evolve in postural control development. The repetition of activated programs, a set of stimuli, applied to change the posture with anatomical centration of the joint under various conditions in leading to better support of postural stabilization while seated, while getting up, stepping forward, and standing, in order to teach the patients to use the acquired motor skills automatically in daily life. PNF is a method used for learning effective movement patterns with high biomechanical effectiveness based on repetitive stimulation of cooperating alfa-motoneurons and proprioceptors in muscle, tendons and joint capsules. Therapy will be individualized and led in the standard face-to-face regiment.
Study: NCT06478862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: The 10 patients recruited in each of the cohorts will receive intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Subjects who complete the 6-cycle Treatment Phase have the option to continue to receive Promitil until disease progression, death, unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: The 10 patients recruited in each of the cohorts will receive intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Subjects who complete the 6-cycle Treatment Phase have the option to continue to receive Promitil until disease progression, death, unacceptable toxicity or withdrawal of consent.
Study: NCT05269186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality software
Description: The patient will undergo a 20-minute virtual reality session before the planning CT scan
Study: NCT05014152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-temp-w1
Description: Q-temp-w1 is a contact type body temperature patch developed by Quanta Computer Co., Ltd. It is mainly used to measure the body temperature of the human body. It can be used for general body temperature measurement, home temperature measurement records and medical tracking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omron thermometer(MC-171W)
Description: Omron thermometer(MC-171W) is mainly used to measure the body temperature of the human body. The reference temperature patch used in this study is the OMRON thermometer, model: MC-171W.
Study: NCT04692922

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI will include structural sequences (e.g., T1 weighted imaging, T2 weighted imaging, T2 FLAIR, diffusion weighted imaging with apparent diffusion coefficient, susceptibility weighted imaging, and diffusion tensor imaging). Using the structural sequences we will make note of the types of brain lesions (e.g., ischemic stroke, hemorrhage, hypoxic-ischemic brain injury), and the locations of these brain lesions. MRI will also include fMRI under three conditions: while the patient is at rest (to evaluate resting state functional connectivity), while the patient is exposed to auditory stimuli (to evaluate passive fMRI responses to stimuli), and while the patient is asked to follow commands (to evaluate active fMRI responses to tasks).

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG
Description: The EEG will include resting, stimulus-based, and task-based assessments of brain function.
Study: NCT05310253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: pill of fludrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: pill of fludrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: pill of fludrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: pill of fludrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo pill

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Description: psychosocial stress induction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Description: psychosocial stress induction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Description: psychosocial stress induction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Description: psychosocial stress induction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo Trier Social Stress Test (P-TSST)
Description: control condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo Trier Social Stress Test (P-TSST)
Description: control condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo Trier Social Stress Test (P-TSST)
Description: control condition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo Trier Social Stress Test (P-TSST)
Description: control condition
Study: NCT06560333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N0892
Description: 1 tablet of Forxiga® 10mg, 1 tablet of Januvia® 100mg and 1 tablet of Glifage XR® 1000mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Januvia® + Glifage XR® + Placebo
Description: 1 tablet of Januvia® 100mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Forxiga ®10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forxiga® + Glifage XR® + Placebo
Description: 1 tablet of Forxiga ®10mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Januvia ® 100mg
Study: NCT05815602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ebastine
Description: Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duspatalin
Description: Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo.
Study: NCT05733936

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation protocol
Description: rehabilitation protocols after ACLR have been described, aiming to improve muscle strength and knee stability through muscle strengthening exercises in addition to exercises to improve joint proprioception
Study: NCT04863378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking conversational reminiscence
Description: Triadic walking with prompted conversational reminiscence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking conversational reminiscence
Description: Triadic walking with prompted conversational reminiscence
Study: NCT05926934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Single strand β-Ti fixed retainer
Description: All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: SS fixed retainer
Description: All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Twisted fixed retainer
Description: All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
Study: NCT05625204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center based attention (stretching only) control
Description: Center based attention (stretching only) control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center based HIIT
Description: Center based HIIT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based HIIT
Description: Home based HIIT
Study: NCT06488274

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New infant formula
Description: The new formula will be given to infants during the 4-month study period.
Study: NCT06470139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution
Description: 20ml 0.2% Ropivacaine + 2.0ml 0.9% NaCl
Study: NCT05733936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation protocol
Description: rehabilitation protocols after ACLR have been described, aiming to improve muscle strength and knee stability through muscle strengthening exercises in addition to exercises to improve joint proprioception
Study: NCT06128798

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Impact
Description: A serving of 74 gm (containing 309 kcal ) of oral impact mixed with 250 ml of water. Each participant will receive total of 3 servings daily for 7 days pre operatively .

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutren Optimum
Description: A serving of 66.8 gm ( containing 304 kcal ) of nutren optimum mixed with 300 ml of water.Each participant will receive total of 3 servings daily for 7 days pre operatively .
Study: NCT04247750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 0.5 mg
Description: Daily administration of 1 or more tablets
Study: NCT05989646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral TENS
Description: Sacral TENS applied two hours daily for 10 weeks
Study: NCT04715035

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy interventions
Description: mobilization, stretch, education, eccentric exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy interventions
Description: mobilization, stretch, education, eccentric exercises
Study: NCT06238245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: ATG (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-HSCT. ATG (1.5 mg/kg, day -5; 2.5 mg/kg, day -4; mathematical function was then exploited to determine the total targeted ATG dose on day -3 to -2 based on concentrations of active ATG on day -5 to -4) was used in both haploidentical donor-HSCT and mismatched unrelated donor-HSCT. Reduced-dose PTCy (two doses of 14.5 mg/kg Cy was given on days +3 and +4 post-HSCT) was used of GVHD prophylaxis.
Study: NCT05500924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: 5 sets of functional activities each will be repeated for 3 times , while the therapist is performing mulligan mobilization techniques Sit to stand Squat Stand to sit Stairs stepping Bridging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: 5 sets of functional activities each will be repeated for 3 times , while the therapist is performing mulligan mobilization techniques Sit to stand Squat Stand to sit Stairs stepping Bridging
Study: NCT06470139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution + 4mg Dexamethasone
Description: 20ml 0.2% Ropivacaine + 4mg Dexamethasone
Study: NCT06357949

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity laser
Description: All patients will receive a rehabilitation program consisting of stretching, strengthening, balance, and walking exercises targeting the lower extremities for 45 minutes, 5 days a week, for 6 weeks. Walking training will initially begin on level ground and gradually progress to different levels and surfaces.~High-intensity laser will be applied continuously in biostimulation mode 3 days a week, once a day, for a total of 9 sessions over 3 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: The same procedure will be followed, but sham laser will be applied at 0 j/cm2 for 10 minutes.
Study: NCT04494633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Encounters Medical School 3D Simulation
Description: A 3D simulation related to coping with the stresses of medical school and burnout.
Study: NCT04966637

Intervention type: OTHER
Intervention: COPD cohort
Description: as this a retrospective descriptive study no intervention will be administered to study participants
Study: NCT06290635

Intervention type: DIAGNOSTIC_TEST
Intervention: Breathlessness Assessment Tool
Description: Participants will complete a breathlessness assessment tool (questionnaire) at three timepoints over the study duration, among other validated questionnaires.
Study: NCT06081998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: 25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Study: NCT06512649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early intervention
Description: 90-minute parent-coaching session once a week for 6 months with an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention. The intervention is individualized and tailored to each child's needs and identifies with caregivers the ways to embody objectives in daily life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active monitoring
Description: 90-minute session once a month for 6 months. Sessions will be performed by an expert developmental therapist, supported by a child neuropsychiatrist or psychologist. A parent will always be present and actively involved in the intervention.
Study: NCT05632627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The current study will directly test the hypothesis that a moderate dose of CBD leads to improvements in cognition, TBI-related symptoms, pain, sleep, depression, anxiety, and peripheral markers of inflammation and oxidative stress.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The current study will directly test the hypothesis that a moderate dose of CBD leads to improvements in cognition, TBI-related symptoms, pain, sleep, depression, anxiety, and peripheral markers of inflammation and oxidative stress.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study: NCT06063408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy
Description: Cognitive functional therapy (CFT) is a novel intergraded behavioral approach for individualizing the management of spinal pain, targeting the bio-psycho-social factors of rehabilitation, and enabling the patient to self-manage the condition.~CFT lies within the broad spectrum of the biopsychosocial approach for the management of spinal pain. CFT uses a multidimensional clinical reasoning framework with aim to enable the clinician to identify modifiable components of the condition, evaluate patients' behavioral responses to pain, and compose and drive a tailored rehabilitation program mainly based on self-management. The intervention is comprised by the interplay on making sense of pain, exposure with control, and lifestyle change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Each individual session involve a combination of pain management with electrotherapy, massage and relaxation techniques. Also include some posture exercise these will be targeted on body alignment to the neutral position, and strengthening the whole neck area. strengthening program will be include isometrics on all cervical movements with a band which progressively increase the resistance of the band by change it and process to exercise against the band resistant. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
Study: NCT05944991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive oil message
Description: Message of olive oil 2 times daily
Study: NCT05098457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GP0112
Description: Injectable gel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Lyft Lidocaine
Description: Injectable gel
Study: NCT06101277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablative local therapy
Description: Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
Study: NCT05175924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nanpharmacological method
Description: Virtual Reality
Study: NCT04601233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector
Description: Self injection testosterone treatment
Study: NCT04475250

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetragraph (TM) NMT Monitor
Description: TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
Study: NCT05857462

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-admission FICB
Description: Post-admission supra-inguinal FICB in hip fracture patient with 0.33% bupivacaine 30 ml
Study: NCT04786964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosibelimab
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study: NCT05619016

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-ABY-025 PET
Description: \[68Ga\]Ga-ABY-025 PET: Each patient in Cohort 1 will be imaged with a PET/CT twice using the radiolabeled investigational product ABY-025 as a tracer. At the time of injection, a 45-minutes long dynamic scan will take place over a pre specified region of interest. Three hours after injection a full body PET scan followed by a CT scan will be performed.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biopsy and analysis of HER2 expression
Description: Biopsy: Within 3 days after the first ABY-025-PET a tissue sample from at least one metastasis \>10 mm available for biopsy, preferably shallow lymph nodes, will be analyzed for HER2 expression through immunohistochemistry- (IHC) and in situ hybridization- (ISH) analysis in patients with GEAC and HER2low mBC.
Study: NCT06042439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 weeks of exercise training (Pre-training)
Description: handgrip and treadmill walking 4 days per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 weeks of exercise training (Pre-training)
Description: handgrip and treadmill walking 4 days per week